NCT00551850View on ClinicalTrials.gov

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

May 31, 2010

Conditions
Advanced CancerRefractory Cancer
Interventions
DRUG

AV-412

oral solid dosage form administered three times weekly for 4 weeks (1 cycle)

Trial Locations (4)

10461

Montefiore Medical Center, New York

20007

Georgetown University Hospital, Washington D.C.

66160

Kansas Masonic Cancer Research Center, Kansas City

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

AVEO Pharmaceuticals, Inc.

INDUSTRY